Skip to main content
Latest news
Browse specialties
Breast cancer Genitourinary cancers Lung & thoracic cancers
In focus
Next-generation sequencing: Emerging biomarkers in thyroid and NSCLCs ctDNA and bladder cancer: Current understanding and beyond ROS1 fusion-positive NSCLC NSCLC driver mutations: Discussing the importance of RET, ALK and ROS1 alterations in NSCLC Early-stage NSCLC management: Surgery, targeted treatment and immunotherapy ALK fusion-positive NSCLC: International approaches to management RET fusion-positive NSCLC: Informing on the use of pralsetinib for patients with RET fusion-positive, advanced NSCLC COVID-19 & cancer
Conferences
SABCS 2022 ESMO 2022 2022 ASCO Annual Meeting
About us
Medicine Matters Oncology
EXTENDED SEARCH
Top

21-04-2017 | Nausea and vomiting | Review | Article

Management of Chemotherapy-Induced Nausea and Vomiting in Pediatric Patients

Journal: Pediatric Drugs

Author: Rudolph M. Navari

Publisher: Springer International Publishing

Login to get access

Abstract

Chemotherapy-induced nausea and vomiting (CINV) is associated with a significant deterioration in quality of life and is perceived by patients as a major adverse effect of the treatment. This review summarizes the safety and efficacy of current antiemetic agents for the prevention of CINV in children. Information on antiemetic prophylaxis for CINV in children was obtained from a literature review of current peer-reviewed articles and recent international guidelines. The literature review and the international antiemetic guidelines provide recommendations for use of specific antiemetics in children based on the emetogenicity of the chemotherapy. 5-Hydroxytryptamine-3 (5-HT3) receptor antagonists have been safe and effective in the prevention of acute emesis with a few patients experiencing mild headache. No adequate studies have been conducted to date for specific recommendations for the prevention of delayed nausea and vomiting in children. The neurokinin (NK)-1 receptor antagonist aprepitant has been approved by the US FDA for use in children of a specific age and weight. No studies for the NK1 receptor antagonists netupitant and rolapitant in children have been conducted. Olanzapine, an antipsychotic, has been shown to be safe and effective in preventing nausea and emesis in adult patients receiving chemotherapy. Its use in children has been limited to children with poor control of CINV; more studies are necessary in this population. In conclusion, practitioners should follow international antiemetic guidelines to provide patients with the specific antiemetics in the recommended dose for the highest possible quality of care.
Literature
1.
Navari RM, Aapro M. Antiemetic prophylaxis for chemotherapy-induced nausea and vomiting. N Engl J Med. 2016;374:1356–67.CrossRefPubMed
2.
Navari RM. Management of chemotherapy-induced nausea and vomiting: focus on new agents and new uses for older agents. Drugs. 2013;73:249–62.CrossRefPubMed
3.
Dupuis LL, Boodhan Sung, et al. Guideline for the classification of the acute emetogenic potential of antineoplastic medication in pediatric cancer patients. Pediatr Blood Cancer. 2011;57:191–8.CrossRefPubMed
4.
Dupuis LL, Sung L, Moassiotis A, et al. 2016 updated MASCC/ESMO consensus recommendations: prevention of chemotherapy-induced nausea and vomiting in children. Support Care Cancer. 2017;25:323–31.CrossRefPubMed
5.
Jordan K, Roila F, Molassiotis A, et al. Antiemetics in children receiving chemotherapy. MASCC/ESMO guideline update 2009. Support Care Cancer. 2011;19:537–42.CrossRef
6.
Dupuis LL, Boodham S, Holdsworth M et al. Guideline for the prevention of acute nausea and vomiting due to antineoplastic medications in pediatric cancer patients. Pediatr Blood Cancer 2013;60:1073-82.CrossRefPubMed
7.
Navari RM. Treatment of chemotherapy-induced nausea. Community Oncol. 2012;9:20–6.CrossRef
8.
Navari RM, Qin R, Ruddy RJ, et al. Olanzapine for the prevention of chemotherapy-induced nausea and vomiting. N Engl J Med. 2016;375:134–42.CrossRefPubMedPubMedCentral
9.
Stern RM, Koch KL, Andrews PLR, editors. Nausea: mechanisms and management. New York: Oxford University Press; 2011.
10.
Lau Moon Lin M, Robinson PD, Flank J, et al. The safety of prochlorperazine in children: a systematic review and meta-analysis. Drug Saf. 2016;39:509–16.CrossRefPubMed
11.
Simpson K, Spencer CM, McClellan KJ. Topisetron: an update of its use in the prevention of chemotherapy-induced nausea and vomiting. Drugs. 2000;59:1297–315.CrossRefPubMed
12.
Kimura E, Niimi E, Watanabe A, et al. Study on clinical effect of a continuous intravenous infusion of azasetron against nausea and vomiting induced by anticancer drugs including CDDP. Gan To Kagaku Ryoho. 1996;23:477–81.PubMed
13.
Taguchi T, Tsukamoto F, Watanabe T, et al. Usefulness of ramosetron hydrochloride on nausea and vomiting in CMF or CEF therapy for breast cancer. Gan To Kagaku Ryoho. 1999;26:1163–70.PubMed
14.
Hesketh PJ. Comparative review of 5-HT3 receptor antagonists in the treatment of acute chemotherapy-induced nausea and vomiting. Cancer Invest. 2000;18:163–73.CrossRefPubMed
15.
Phillips RS, Friend AJ, Gibson F, et al. Antiemetic medication for the prevention and treatment of chemotherapy-induced nausea and vomiting in childhood. Cochrane Database Syst Rev. 2016;2:CD007786.PubMed
16.
World Health Organization. Dolasetron mesylate and serious cardiovascular reactions. WHO Drug Information. 2006;20(3):185.
17.
US Food and Drug Administration. FDA drug safety communication: abnormal heart rhythms associated with use of anzemet (dolasetron mesylate). https://​www.​accessdata.​fda.​gov/​drugsatfda_​docs/​label/​2011/​020623s009lbl.​pdf. Accessed 21 Mar 2017.
18.
Ondansetron: New Dose Restrictions. Prescriber Update 33(3):21. September 2012. http://​www.​medsafe.​govt.​nz/​profs/​PUArticles/​OndansetronSept2​012.​htm. Accessed 23 Mar 2017.
19.
Freedman SB, Uleryk E, Rumantir M, et al. Ondansetron and the risk of cardiac arrhythmias: a systematic review and post marketing analysis. Ann Emerg Med. 2014;64:19–25.CrossRefPubMed
20.
Yeh YC, Blouin GC, Reddy P. Evidence to support use of palonosetron over generic serotonin type-3 receptor antagonists for chemotherapy-induced nausea and vomiting. Am J Health Syst Pharm. 2014;71:500–6.CrossRefPubMed
21.
Navari RM. The current status of the use of palonosetron. Expert Opin Pharmacother. 2013;14:1281–4.CrossRefPubMed
22.
Navari RM. Palonosetron for the treatment of chemotherapy-induced nausea and vomiting. Expert Opin Pharmacother. 2015;15:2599–608.CrossRef
23.
Rojas C, Thomas AG, Alt J, et al. Palonosetron triggers 5-HT3 receptor internalization and causes prolonged inhibition of receptor function. Eur J Pharmacol. 2010;626:193–9.CrossRefPubMed
24.
Kovacs G, Wachtel AE, Basharova EV, et al. Palonosetron versus ondansetron for the prevention of chemotherapy-induced nausea and vomiting in pediatric patients with cancer receiving moderately or highly emetogenic chemotherapy: a randomized, phase 3, double blind, double dummy, non-inferiority study. Lancet Oncol. 2016;17:332–44.CrossRefPubMed
25.
Lau Moon Lin M, Robinson PD, Flank J, et al. The safety of metoclopramide in children: a systematic review and meta-analysis. Drug Saf. 2016;39:675–87.CrossRefPubMed
26.
European Medicine Agency. Metoclopramide use recommendations. London: EMA; 26 July 2013. http://​www.​ema.​europa.​eu/​ema/​index.​jsp?​curl=​pages/​news_​and_​events/​news/​2013/​. Accessed 23 Mar 2017.
27.
Flank J, Robinson PD, Holdsworth M, et al. Guidelines for the treatment of breakthrough and the prevention of refractory chemotherapy-induced nausea and vomiting in children with cancer. Pediatr Blood Cancer. 2016;63:1144–51.CrossRefPubMed
28.
Bakhshi S, Batra A, Biswas B, et al. Aprepitant as an add-on therapy in children receiving highly emetogenic chemotherapy: a randomized, double-blind, placebo-controlled trial. Support Care Cancer. 2015;23:3229–37.CrossRefPubMed
29.
Kang HJ, Loftus S, Taylor A, et al. Aprepitant for the prevention of chemotherapy-induced nausea and vomiting in children: a randomized, double-blind, phase 3 trial. Lancet Oncol. 2015;16:585–94.CrossRef
30.
Navari RM. Fosaprepitant (MK-0517): a neurokinin-1 receptor antagonist for the prevention of chemotherapy-induced nausea and vomiting. Expert Opin Investig Drugs. 2007;16:1977–85.CrossRefPubMed
31.
Grunberg S, Chua D, Maru A, et al. Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with cisplatin therapy: randomized, double-blind study protocol—EASE. J Clin Oncol. 2011;29:1495–501.CrossRefPubMed
32.
Shillingburg A, Biondo L. Aprepitant and fosaprepitant use in children and adolescence at an academic medical center. J Pediatr Pharmacol Ther. 2014;19:127–31.PubMedPubMedCentral
33.
Aapro M, Carides A, Rapoport BL, et al. Aprepitant and fosaprepitant: a 10 year review of efficacy and safety. Oncologist. 2015;20:450–8.CrossRefPubMedPubMedCentral
34.
Navari RM. Profile of netupitant/palonosetron fixed dose combination (NEPA) and its potential in the treatment of chemotherapy-induced nausea and vomiting (CINV). Drug Des Devel Ther. 2015;9:155–61.PubMed
35.
Navari RM. Rolapitant for the treatment of chemotherapy-induced nausea and vomiting. Expert Rev Anticancer Ther. 2015;15:1127–33.CrossRefPubMed
36.
Fulton B, Goa KL. Olanzapine: a review of its pharmacological properties and therapeutic efficacy in the management of schizophrenia and related psychoses. Drugs. 1997;53:281–98.CrossRefPubMed
37.
Bymaster FP, Calligaro D, Falcone J. Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology. 1996;14:87–96.CrossRefPubMed
38.
Stephenson CME, Pilowsky LS. Psychopharmacology of olanzapine: a review. Br J Psychiatry. 1999;174:52–8.
39.
Breithart W, Tremblay A, Gibson C. An open trial of olanzapine for the treatment of delirium in hospitalized cancer patients. Psychosomatics. 2002;43:175–82.CrossRef
40.
Bymaster FP, Falcone JF, Bauzon D, et al. Potent antagonism of 5-HT (3) and 5-HT(6) receptors by olanzapine. Eur J Pharmacol. 2001;430:341–9.CrossRefPubMed
41.
Rudd JA, Ngan MP, Wai MK, et al. Anti-emetic activity of ghrelin in ferrets exposed to the cytotoxic anti-cancer agent cisplatin. Neurosci Lett. 2006;392:79–83.CrossRefPubMed
42.
Yakabi K, Sadakane C, Noguchi M, et al. Reduced ghrelin secretion in the hypothalamus of rats due to cisplatin-induced anorexia. Endocrinology. 2010;151:3773–82.CrossRefPubMed
43.
Hurren KM, Berlie HD. Lorcaserin: an investigational serotonin 2C agonist for weight loss. Am J Health Syst Pharm. 2011;68:2029–37.CrossRefPubMed
44.
Allison DB, Casey DE. Antipsychotic-associated weight gain: A review of the literature. J Clin Psychiatry. 2001;62:22–31.PubMed
45.
Hale AS. Olanzapine. Br J Hosp Med. 1997;58:443–5.
46.
Goldstein LE, Sporn J, Brown S, et al. New-onset diabetes mellitus and diabetic ketoacidosis associated with olanzapine treatment. Psychosomatics. 1999;40:438–43.CrossRefPubMed
47.
Flank J, Thackray J, Nielson D, et al. Olanzapine for treatment and prevention of acute chemotherapy-induced vomiting in children: a retrospective, multi-center review. Pediatr Blood Cancer. 2016;62:496–501.CrossRef
48.
Flank J, Sung L, Dvorak C, et al. The safety of olanzapine in young children. A systematic review and meta-analysis. Drug Saf. 2014;37:791–804.CrossRefPubMed